DPT and Confab complete US$10m investment
To add a compounding suite in San Antonio, Texas and a new laboratory in Montreal, Canada
DPT Laboratories, a US-based contract development and manufacturing organisation (CDMO) specialising in semi-solid and liquid dosage forms, and its subsidiary Confab, which specialises in complex solids, semi-solids and liquids, have completed a combined US$10m capital investment.
San Antonio-based DPT has invested in a new compounding suite and significant upgrades to production filling lines that will increase capacity, throughput and precision. Additional upgrades include a remodelled front office area and enhanced security to further restrict access to the manufacturing floor and further enhance GMP compliance.
Montreal-based Confab made a 'significant investment' to increase R&D capabilities with a new state-of-the-art laboratory, new equipment and expansion of its R&D team. Confab can now offer customers pharmaceutical development capabilities ranging from formulation development and analytical method development to technology transfers at commercial scale.
'The investments in capital demonstrate our continuing commitment to provide high-quality development and manufacturing solutions to our partners,' said Paul Josephs, Senior Vice President of Sales, Marketing and Corporate Development.